HIV and ID Observations

October 30th, 2014

Why the IPERGAY (Yes, That’s Its Name) Study Could Substantially Increase Use of PrEP

Yesterday, the French IPERGAY study of intermittent pre-exposure prophylaxis (PrEP) was stopped early by the Data Safety Monitoring Board, and for the best reason — the evidence demonstrating that it prevented HIV was overwhelming. For those who read French, here’s the official announcement. (Scroll down for the English.) And for those who can’t believe the name, it stands […]

---

July 13th, 2011

More Favorable Results on PrEP, But …

As part of the usual flurry of studies released just before major scientific meetings, results of two pre-exposure prophylaxis (PrEP) trials in heterosexual men and women have just been made public: In the CDC TDF2 study, 1200 HIV-uninfected men and women in Botswana were randomized to take oral tenofovir/FTC or placebo daily. Tenofovir/FTC was found to reduce the […]

---

February 27th, 2011

CROI 2011 Starts Today

With a fresh 4 inches of snow on the ground in Boston, the 18th Conference on Retroviruses and Opportunistic Infections (CROI) starts today. Pocket program is available here (PDF format).  Based on a (very) quick perusal, we can expect the following: Progress (lots of it) in prevention, with more from CAPRISA and iPrEx and the whole “treatment […]

---

January 28th, 2011

Wow, That Was Fast: PrEP Guidelines Appear

With the ink barely dry on iPrEx — still tricky to type — along come “interim” guidelines from the CDC on pre-exposure prophylaxis (PrEP). Based on the results [iPrEx], CDC and other U.S. Public Health Service (PHS) agencies have begun to develop PHS guidelines on the use of PrEP for MSM at high risk for HIV […]

---